Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 5, 2010, Pages 586-597

  Raje, Noopur ^a   Vallet, Sonia ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2A; CHIMERIC PROTEIN; FC RECEPTOR; SOTATERCEPT; UNCLASSIFIED DRUG;

ANEMIA; BONE DENSITY; BREAST ADENOCARCINOMA; CARCINOMA CELL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING SITE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG WITHDRAWAL; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSTMENOPAUSE; REVIEW; SINGLE DRUG DOSE;

ACTIVIN RECEPTORS, TYPE II; ANEMIA; ANIMALS; BONE DISEASES, METABOLIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS;

MURINAE;

EID: 77957734208     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis. Shiozaki M, Sakai R, Tabuchi M, Nakamura T, Sugino K, Sugino H, Eto Y PROC NATL ACAD SCI USA 1992 89 5 1553-1556
2. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. Yamashita H, Tendijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin CH, Miyazono K J CELL BIOL 1995 130 1 217-226
3. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang OH et al N ENGL J MED 2001 344 19 1434-1441
4. Acceleron initiates phase 1 clinical trial of ACE-011, a novel treatment for bone loss; Acceleron becomes a clinical-stage company. Acceleron Pharma Inc PRESS RELEASE 2006 June 21
5. ACE-011 improves multiple myeloma bone disease in a preclinical model. Acceleron Pharma Inc PRESS RELEASE 2007 June 26
6. Acceleron Pharma announces global collaboration with Celgene Corporation on ACE-011 program for cancer-related bone loss. Acceleron Pharma Inc PRESS RELEASE 2008 February 20
7. Acceleron Pharma and Celgene Corporation receive Hart-Scott-Rodino clearance for ACE-011 collaboration. Acceleron Pharma Inc PRESS RELEASE 2008 March 24
8. Treatment with RAP-011 (a soluble activin receptor type IIA) increases bone mineral density in mice with prior bisphosphonate exposure. Pearsall RS, Mangini M, Cornwall-Brady M, Monnell T, Marvell T, Haigis B, Kumar R, Underwood KW, Seehra J BONE 2008 42 Suppl 1 Abs 144
9. RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss in a mouse model of metastatic breast cancer. Mulivor AW, Cornwall-Brady M, Kumar R, Pearsall AE, Underwood KW, Ucran J, Sherman ML, Seehra J, Pearsall RS AM ASSOC CANCER RES ANN MEET 2008 99 April 15 Abs 4068
10. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V et al PROC NATL ACAD SCI USA 2008 105 19 7082-7087 • Describes the construction and puriflcation of RAP-011 and the inhibitory potency of the fusion protein against activin A. In vivo studies evaluating the effects of RAP-011 in ovariectomized mice with established bone loss are also presented.
11. Metastasis to bone: Causes, consequences and therapeutic opportunities. Mundy GR NAT REV CANCER 2002 2 8 584-593
12. Celgene Corporation and Acceleron Pharma initiate phase 2 study of ACE-011 in patients with multiple myeloma. Celgene Corp PRESS RELEASE 2008 October 16
13. Celgene Corp: Form 10-K for the year ended 31 December 2008. Celgene Corp FORM 10-K 2009 February 17
14. RAP-011, a soluble activin receptor type IIA murine IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastases in a mouse model of metastatic breast cancer. Mulivor AW, Barbosa D, Kumar R, Pearsall AE, Underwood KW, Ucran JA, Seehra J, Pearsall R BONE 2009 44 Suppl 2 Abs OC 27
15. Acceleron and Celgene initiate phase 2 study of ACE-011 to treat chemotherapy-induced anemia. Acceleron Pharma Inc; Celgene Corp PRESS RELEASE 2009 July 28
16. ACE-011, a soluble activin receptor type IIA IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: Preliminary analysis. Abdulkadyrov KM, Salogub GN, Khuazheva MK, Woolf R, Haltom E, Borgstein NG, Knight R, Renshaw G, Yang Y, Sherman ML BLOOD 2009 114 22 Abs 749 • Presents preliminary results from a phase IIa clinical trial in patients with stage II/III MM. Sotatercept (0.1, 0.3 and 0.5 mg/kg sc, q4w for 4 months) dose-dependently increased hemoglobin levels and 7 of 22 evaluable patients experienced either complete or very good partial responses.
17. The use of RAP-011, a novel bone anabolic agent, in combination with parathyroid hormone or zoledronic acid using a mouse model of established bone loss. Cornwall-Brady M, Mangini M, Barbosa D, Mazzola L, Marvell T, Milling J, Haigis B, Kumar R, Underwood K, Pearsall RS J BONE MINER RES 2007 22 Suppl 1 Abs S394
18. RAP-011 (a soluble activin receptor type IIA) increases bone mineral density in combination with prior antiresorptive therapy. Mangini M, Comwall-Brady M, Pullen A, Halley K, Monnell T, Milling J, Haigis B, Kumar R, Underwood K, Pearsall RS J BONE MINER RES 2007 22 Suppl 1 Abs W312
19. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Li QL, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM MOL HUM REPROD 2007 13 9 675-683
20. ACE-011, a soluble activin receptor type IIA fusion protein, increases BMD and improves microarchitecture in cynomolgus monkeys. Fajardo RJ, Bouxsein ML, Pearsall AE, Grinberg A, Davies M, Monnell T, Ucran J, Barazza M, Kelly C, Khanzode D, Underwood K et al J BONE MINER RES 2007 22 Suppl 1 Abs 1230
21. A single dose of ACE-011 is associated with increases in bone formation and decreases in bone resorption markers in healthy, postmenopausal women. Ruckle J, Jacobs M, Kramer W, Kumar R, Underwood K, Pearsall RS, Pearsall A, Seehra J, Condon C, Sherman ML J BONE MINER RES 2007 22 Suppl 1 Abs 1132
22. Soluble activin receptor type IIA fusion protein, ACE-011, increases bone mass by stimulating bone formation and inhibiting bone resorption in cynomolgus monkeys. Lotinun S, Fajardo RJ, Pearsall RS, Bouxsein ML, Baron R J BONE MINER RES 2008 23 Suppl Abs SU 376
23. RAP-011, a soluble activin receptor type IIA, stimulates osteoblast differentiation and inhibits osteoclast development. Pearsall RS, Werner ED, Kumar R, Davies M, Pobre E, Haigis B, Underwood KW, Seehra J CALCIF TISSUE INT 2008 82 Suppl 1 Abs Mo-P143
24. RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastases in a mouse model of metastatic breast cancer. Mulivor A, Kumar R, Pearsall A, Underwood K, Ucran J, Sherman M, Seehra J, Pearsall RS CANCER TREAT REV 2008 34 Suppl 1 Abs P51
25. RAP-011, a soluble activin receptor type IIA IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone disease in multiple myeloma. Chantry A, Heath D, Coulton L, Gallagher O, Evans H, Vanderkerken K, Seehra JS, Croucher PI CLIN EXP METASTASIS 2008 25 Suppl 1 Abs P86
26. ACE-011, a soluble activin receptor type IIa IgG-Fc fusion protein, increases hemoglobin and hematocrit levels in postmenopausal healthy women. Kim KT, Borgstein NG, Yang YJ, Haltom E, Mook L, Ababa MD, Reddy SK, Sherman ML BLOOD 2008 112 11 Abs 3866
27. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang YJ, Condon CH, Sherman ML J BONE MINER RES 2009 24 4 744-752 •• Presents data from healthy postmenopausal women demonstrating that sotatercept (1 and 3 mg/kg iv and 0.1 mg/kg sc) reduced FSH levels and increased BSALP and PINP levels. Safety and tolerability data are also provided.
28. RAP-011, a soluble activin receptor type IIA IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastases in a mouse model of metastatic breast cancer. Mulivor AW, Barbosa D, Kumar R, Pearsall AE, Underwood KW, Ucran JA, Seehra J, Pearsall RS CANCER RES 2009 69 2 Suppl Abs 1158
29. ACE-011, a soluble activin receptor type IIA IgG-Fc fusion protein, decreases follicle stimulating hormone and increases bone-specific alkaline phosphatase, a marker of bone formation, in postmenopausal healthy women. Borgstein NG, Yang Y, Condon CH, Haltom E, Sherman ML CANCER RES 2009 69 2 Suppl Abs 1160
30. ACE-011, a soluble activin receptor type IIA IgG-Fc fusion protein, increases BMD within 4 months in postmenopausal healthy women. Borgstein NG, Yang Y, Haltom E, Mook L, Bouxsein M, Sherman ML OSTEOPOROSIS INT 2009 20 Suppl 1 Abs P759SA
31. Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Fajardo RJ, Manoharan RK, Pearsall RS, Davies MV, Marvell T, Monnell TE, Ucran JA, Pearsall AE, Khanzode D, Kumar R, Underwood KW et al BONE 2010 46 1 64-71 • The impact of sotatercept on bone mineral density, compressive mechanical properties and ash content is described, along with the pharmacokinetic profile of the fusion protein in cynomolgus monkeys.
32. A soluble activin receptor type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in cynomolgus monkeys. Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, Fajardo RJ, Kumar R, Underwood KW, Seehra J, Bouxsein ML et al BONE 2010 46 4 1082-1088 • Presents in vivo data demonstrating that sotatercept increased osteoblast surface and number, and promoted bone formation. The tolerability of sotatercept in cynomolgus monkeys and effects on biomarkers of bone formation are also described.
33. Effects of RAP-011, a soluble activin receptor, on multiple myeloma (MM) via targeting the microenvironment. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Pozzi S, Santo L, Yan H, Cirstea D, Seehra J, Scadden D, Anderson K et al AM ASSOC CANCER RES ANN MEET 2008 99 April 12 Abs 1521
34. RAP-011, a soluble activin receptor type IIA murine IgG-Fc fusion protein, prevents chemotherapy induced anemia. Mulivor AW, Barbosa D, Kumar R, Sherman ML, Seehra J, Pearsall RS BLOOD 2009 114 22 Abs 161
35. Comparison of a soluble activin receptor type IIA (ACTRIIA), PTH and zoledronate, for treatment of established bone loss in OVX mice. Rosen E, Canalis E, Stadmeyer L, Cory E, Glatt V, Pearsall RS, Bouxsein ML J BONE MINER RES 2007 22 Suppl 1 Abs 1233
36. Pharmacological inhibition of signaling through the activin receptor type IIA prevents primary tumor growth and skeletal metastases in mouse models of breast cancer. Mulivor AW, Barbosa D, Kumar R, Underwood KW, Ucran JA, Seehra J, Pearsall RS CANCER RES 2009 69 24 Suppl 3 Abs 5058
37. Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo. Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, Key ML et al J BONE MINER RES 2010 June 07 DOI: 10.1002/jbmr.142 • The effects of RAP-011 in two different mouse models of MM are presented. RAP-011 had a positive impact on bone loss, tumor burden of the bone and survival time.
38. Pharmacological inhibition of signaling through the activin receptor type IIA heals osteolytic lesions and prevents anemia following chemotherapy. Mulivor A, Barbosa D, Kumar R, Pearsall A, Underwood K, Monnell T, Ucran J, Seehra J, Pearsall R J BONE MINER RES 2009 24 Suppl 1 Abs A09003057
39. A soluble activin type II receptor prevents myeloma bone disease. Chantry A, Heath D, Coulton L, Gallagher O, Evans H, Seehra J, Vanderkerken K, Croucher PI HAEMATOLOGICA 2007 92 6 Suppl 2 Abs PO-319
40. A soluble activin type II receptor prevents the development of myeloma bone disease. Chantry A, Heath D, Coulton L, Evans H, Abdul N, Seehra J, Vanderkerken K, Croucher P CANCER TREAT REV 2008 34 Suppl 1 Abs P3
41. Treatment with a soluble activin type II receptor reverses bone loss in ovariectomized mice. Pearsall RS, Cornwall-Brady M, Lachey J, Glatt V J BONE MINER RES 2006 21 Suppl 1 Abs 1090
42. Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. del Re E, Sidis Y, Fabrizio DA, Lin HY, Schneyer A J BIOL CHEM 2004 279 51 53126-53135
43. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. Allendorph GP, Isaacs MJ, Kawakami Y, Izpisua Belmonte JC, Choe S BIOCHEMISTRY 2007 46 43 12238-12247
44. Functional analysis of activins during mammalian development. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, Bradley A NATURE 1995 374 6520 354-356
45. Activin A is an essential cofactor for osteoclast induction. Fuller K, Bayley KE, Chambers TJ BIOCHEM BIOPHYS RES COMMUN 2000 268 1 2-7
46. The activin A-follistatin system: Potent regulator of human extracellular matrix mineralization. Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden AG, van der Spek PJ, Visser JA, de Jong FH, Pols HAP, van Leeuwen JP FASEB J 2007 21 11 2949-2960
47. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC ENDOCRINOLOGY 2002 143 1 74-83
48. Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y J CELL BIOCHEM 1999 75 2 206-214
49. Local administration of activin promotes fracture healing in the rat fibula fracture model. Sakai R, Miwa K, Eto Y BONE 1999 25 2 191-196
50. Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Sakai R, Fujita S, Horie T, Ohyama T, Miwa K, Maki T, Okimoto N, Nakamura T, Eto Y BONE 2000 27 1 91-96
51. Inhibin A is an endocrine stimulator of bone mass and strength. Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, Swain FL, Skinner RA, Hogue WR, Nicks KM, Pierson TM, Suva LJ et al ENDOCRINOLOGY 2007 148 4 1654-1665
52. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R CANCER 2007 110 8 1860-1867
53. Bone metastasis from gynecologic carcinomas: A clinicopathologic study. Abdul-Karim FW, Kida M, Wentz WB, Carter JR, Sorensen K, Macfee M, Zika J, Makley JT GYNECOL ONCOL 1990 39 2 108-114
54. Skeletal complications of malignancy. Coleman RE CANCER 1997 80 8 Suppl 1588-1594
55. Parathyroid hormone-related protein induces spontaneous osteoclast formation via a paracrine cascade. Nakchbandi IA, Weir EE, Insogna KL, Philbrick WM, Broadus AE PROC NATL ACAD SCI USA 2000 97 13 7296-7300
56. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E J SURG RES 2001 100 1 18-24
57. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V BLOOD 2005 106 7 2472-2483
58. IL-1 mediates TNF-induced osteoclastogenesis. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL J CLIN INVEST 2005 115 2 282-290
59. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Lu Y, Cai Z, Xiao GZ, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J CANCER RES 2007 67 8 3646-3653
60. Osteoclasts are active in bone forming metastases of prostate cancer patients. Roato I, D'Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini R PLOS ONE 2008 3 11 e3627
61. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. Tian E, Zhan FH, Walker R, Rasmussen E, Ma YP, Barlogie B, Shaughnessy JD Jr N ENGL J MED 2003 349 26 2483-2494
62. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D et al BLOOD 2004 104 8 2484-2491
63. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA STEM CELLS 2006 24 4 986-991
64. Anemia of chronic disease. Weiss G, Goodnough LT N ENGL J MED 2005 352 10 1011-1023
65. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M et al LANCET 2009 373 9674 1532-1542
66. FSH directly regulates bone mass. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A et al CELL 2006 125 2 247-260
67. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A et al PROC NATL ACAD SCI USA 2010 107 11 5124-5129
68. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Clezardin P, Ebetino FH, Fournier PG CANCER RES 2005 65 12 4971-4974
69. ACE-011, a soluble activin type IIA receptor IgG-Fc fusion protein, significantly increases bone mineral density in healthy postmenopausal women with normal or low bone mass. Borgstein NG, Yang Y, Mook L, Haltom E, Wilson DM, Sherman ML BONE 2010 47 Suppl 2 Abs S40
70. RAP-011, a soluble activin receptor type IIA IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone loss and skeletal metastatses in a mouse model of metastatic breast cancer. Mulivor AW, Barbosa D, Kumar R, Pearsall AE, Underwood KW, Ucran JA, Seehra J, Pearsall RS CANCER RES 2009 69 2 Suppl Abs 1158
71. Comparison of a soluble activin receptor type IIA (ACTRIIA), PTH and zoledronate for treatment of established bone loss in OVX mice. Rosen E, Pearsall S, Glatt V, Bouxsein ML BONE 2007 40 6 S158
72. Products - ACE-011 (Treatment of anemia). Acceleron Pharma Inc COMPANY WORLD WIDE WEB SITE 2010 September 06
73. Product Pipeline. Celgene Corp COMPANY WORLD WIDE WEB SITE 2010 February 17
74. Regulation of cellular and system function by activin. Woodruff TK BIOCHEM PHARMACOL 1998 55 7 953-963
75. TGF-β signaling in tumor suppression and cancer progression. Derynck R, Akhurst RJ, Balmain A NAT GENET 2001 29 2 117-129
76. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Yu J, Shao LE, Lemas V, Yu AL, Vaughan J, Rivier J, Vale W NATURE 1987 330 6150 765-767
77. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFβ family. Maguer-Satta V, Bartholin L, Jeanpierre S, Ffrench M, Martel S, Magaud JP, Rimokh R EXP CELL RES 2003 282 2 110-120
78. Effect of activin A on globin gene expression in purified human erythroid progenitors. Shao L, Frigon NL, Young AL, Yu AL, Mathews LS, Vaughan J, Vale W, Yu J BLOOD 1992 79 3 773-781
79. Interleukin-1 β enhances and interferon-γ suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts. Abe M, Shintani Y, Eto Y, Harada K, Fujinaka Y, Kosaka M, Matsumoto T CLIN EXP IMMUNOL 2001 126 1 64-68
80. Activin A stimulates IκB-α/NFκ B and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. Sugatani T, Alvarez UM, Hruska KA J CELL BIOCHEM 2003 90 1 59-67
81. Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. Hashimoto M, Shoda A, Inoue S, Yamada R, Kondo T, Sakurai T, Ueno N, Muramatsu M J BIOL CHEM 1992 267 7 4999-5004
82. Activin A regulates the production of mature interleukin-1p and interleukin-1 receptor antagonist in human monocytic cells. Ohguchi M, Yamato K, Ishihara Y, Koide M, Ueda N, Okahashi N, Noguchi T, Kizaki M, Ikeda Y, Sugino H, Nisihara T J INTERFERON CYTOKINE RES 1998 18 7 491-498
83. Modulation of endogenous osteogenic protein-1 (OP-1) by interleukin-1 in adult human articular cartilage. Merrihew C, Soeder S, Rueger DC, Kuettner KE, Chubinskaya S J BONE JT SURG SER A 2003 85-A Suppl 3 67-74 (Pubitemid 36951119)
84. Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Virdi AS, Cook LJ, Oreffo ROC, Trifftt JT CELL MOL BIOL 1998 44 8 1237-1246
85. Possible involvement of protein kinases and SMAD2 signaling pathways on osteoclast differentiation enhanced by activin A. Murase Y, Okahashi N, Koseki T, Itoh K, Udagawa N, Hashimoto O, Sugino H, Noguchi T, Nishihara T J CELL PHYSIOL 2001 188 2 236-242
86. Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through SMAD3 and ERK1/ERK2 MAPK signaling pathways. Bao YL, Tsuchida K, Liu B, Kurisaki A, Matsuzaki T, Sugino H J ENDOCRINOL 2005 184 3 493-504
87. Activin inhibits the human PIT-1 gene promoter through the p38 kinase pathway in a SMAD-independent manner. de Guise C, Lacerte A, Rafiei S, Reynaud R, Roy M, Brue T, Lebrun JJ ENDOCRINOLOGY 2006 147 9 4351-4362